BLFSHealthcare · Medical Instruments & SuppliesThe 9 Wall Street analysts covering BioLife Solutions, Inc. hold a median 12-month price target of $31 — -19.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 3 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores BioLife Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (92): The business earns solid, repeatable profits on what it owns.
Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BLFS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −19.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Benchmark | Downgrade | Hold | — |
| 27 July 2026 | Stephens & Co. | Downgrade | Equal-Weight | — |
| 27 July 2026 | Stephens & Co. | Downgrade | Equal-Weight | $32 → $31 |
| 23 July 2026 | Jefferies | Downgrade | Hold | $30 → $31 |
| 23 July 2026 | Jefferies | Downgrade | Hold | — |
| 23 July 2026 | TD Cowen | Downgrade | Hold | — |
| 23 July 2026 | TD Cowen | Downgrade | Hold | $33 → $31 |
| 22 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 22 July 2026 | HC Wainwright & Co. | Downgrade | Neutral | $32 → $31 |
| 22 July 2026 | Lake Street | Downgrade | Hold | — |
| 22 July 2026 | Lake Street | Downgrade | Hold | $33 → $31 |
| 29 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | $32 |
| 29 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Jan 2025 | Northland Capital Markets | Maintains | Outperform | — |
| 19 Dec 2024 | Benchmark | Reiterates | Buy | — |
| 13 Dec 2024 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLFS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, BioLife Solutions, Inc. returned +45.2% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 10% of US stocks
Cheaper than 23% of US stocks
Cheaper than 1% of US stocks
Higher than 71% of US stocks
Higher than 50% of US stocks
Higher than 77% of US stocks
Higher than 57% of US stocks
Higher than 96% of US stocks
Higher than 70% of US stocks
Higher than 44% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioLife Solutions, Inc. has a market value of $1.8B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $102.8M. The latest quarter grew 21.5% year on year.
Net income over the same four quarters: $58.0M, a 56.4% net margin.
Diluted earnings per share, trailing twelve months: $1.16.
Free cash flow in the twelve months to 30 June 2026: −$2.2M.
Trailing P/E: 38.0×; forward P/E: 114.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BioLife Solutions, Inc. employs 155 people — $663K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioLife Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioLife Solutions stockholders approved the company's merger agreement with Repligen Corporation at a special virtual meeting held Oct. 5, 2026. The vote cleared a key shareholder-approval requirement for the proposed transaction.
Why it matters — The shareholder approval removes a major procedural hurdle, moving the proposed Repligen merger closer to completion for BLFS investors.
Law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the adequacy of the price and process in the proposed acquisition of BioLife Solutions by Repligen Corporation. Under the proposed terms, BioLife shareholders would receive $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share.
Why it matters — A BLFS watcher would care because the investigation could raise questions about the fairness of the proposed acquisition price and process for shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. to Repligen Corporation for $11.25 per share in cash plus 0.1442 shares of Repligen common stock. The investigation concerns whether BioLife is obtaining a fair price for its shareholders, and the firm is encouraging shareholders to learn about their rights and options.
Why it matters — A BLFS watcher would care because the investigation raises questions about whether the proposed acquisition price adequately compensates shareholders.
BioLife Solutions, Inc. reported second-quarter earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share. This compares with break-even earnings per share in the same quarter a year earlier.
Why it matters — The results represent a clear improvement over both analyst expectations and the prior-year period, which a BLFS watcher would find notable.
BioLife Solutions reported second quarter 2026 financial results, with total revenue of $28.5 million, up 21% over Q2 2025, GAAP gross margin of 64%, and non-GAAP adjusted EBITDA of $7.4 million. The company also noted that Repligen is expected to acquire BioLife, with the transaction expected to close in the fourth quarter of 2026.
Why it matters — A BLFS watcher would care because the results show revenue growth and profitability, while the announced Repligen acquisition represents a major corporate development expected to close in late 2026.
The 9 Wall Street analysts covering BioLife Solutions, Inc. have a median 12-month price target of $31, with estimates ranging from $31 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering BioLife Solutions, Inc., 1 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioLife Solutions, Inc. 91 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, BioLife Solutions, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies -19.7% from the last close, and Ticker Nerd's factor model ranks BioLife Solutions, Inc. 91 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioLife Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLFS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $33 over the next 12 months.
BioLife Solutions, Inc. returned +45.2% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BioLife Solutions Inc. is a life sciences tools company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry.
The most recent item we track (MarketBeat, 5 Oct 2026): "BioLife Solutions Shareholders Approve Repligen Merger Agreement". BioLife Solutions stockholders approved the company's merger agreement with Repligen Corporation at a special virtual meeting held Oct. 5, 2026. The vote cleared a key shareholder-approval requirement for the proposed transaction.
BioLife Solutions Inc. is a life sciences tools company that develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry. BioLife Solutions Inc. focuses on helping protect the viability and integrity of biologic materials throughout collection, processing, storage, transport, and thawing. Its product portfolio includes biopreservation media, cell-processing consumables, cryogenic storage containers, automated thawing systems, and cold-chain management solutions. These offerings are used by cell therapy developers, biopharmaceutical companies, contract development and manufacturing organizations, biobanks, and research institutions that work with sensitive living cells and other advanced biologic materials. The company serves customers across the United States and international markets, supporting research, clinical development, and commercial manufacturing workflows in regenerative medicine and related fields.
CEO Mr. Roderick de Greef · 155 employees · United States · https://www.biolifesolutions.com
